OSI Pharmaceuticals’ subsidiary, Prosidion Ltd., and Eli Lilly and Co. have entered into a licensing agreement granting Lilly exclusive rights to OSI’s Glucokinase Activator (GKA) program, which includes the lead compound PSN010. Under the terms of the agreement, OSI will receive an upfront fee of $25 million and as much as $360 million in potential development and sales milestones. OSI will also receive royalties on sales of any compounds resulting from the program. GKAs like P...